Which of the following is/are FDA-approved indication(s) for albuterol sulfate (inhalation)? Select All That Apply.

A. Prevention of exercise-induced bronchospasm is a labeled indication for albuterol sulfate. It is administered prophylactically to stabilize mast cells and prevent airway constriction. This ensures patent airways during physical exertion in patients with hyperreactive airway disease. B. Allergic rhinitis involves inflammatory responses in the nasal mucosa rather than the lower respiratory tract. Albuterol is a sympathomimetic bronchodilator and lacks the antihistaminic or anti-inflammatory properties required for this condition. It provides no therapeutic benefit for nasal congestion. C. Relief of bronchospasm in patients with reversible obstructive airway disease is the primary indication. Albuterol acts as a selective beta-2 adrenergic agonist to increase intracellular cyclic adenosine monophosphate. This results in the relaxation of bronchial smooth muscle and rapid bronchodilation. D. Rhinorrhea associated with the common cold is caused by viral-induced nasal inflammation and increased glandular secretion. Albuterol does not possess the anticholinergic or vasoconstrictive effects needed to reduce nasal discharge. Its pharmacological activity is limited to the beta receptors of the bronchi.